Medical Immunology, Pasteur Institute of Iran
Asal Katebi, Ph.D., is an Assistant Professor at the Pasteur Institute of Iran, specializing in Medical Immunology. Her research focuses on developing therapeutic vaccines for infectious diseases like leishmaniasis using nanoparticle formulations and TLR agonists. She holds a Ph.D. in Medical Immunology from Isfahan University of Medical Sciences and has extensive experience in molecular biology and immunotherapy.
Profile
Google Scholar
๐ Education:
Asal Katebi completed her Ph.D. in Medical Immunology at Isfahan University of Medical Sciences, where she conducted research on therapeutic vaccines for leishmaniasis. She also holds an M.Sc. in Medical Immunology from Tehran University of Medical Sciences and a B.Sc. in Microbiology from Islamic Azad University, North Tehran Branch.
๐ฉโ๐ผ Experience:
Dr. Katebi’s professional journey includes significant roles at the Pasteur Institute of Iran, where she conducts research, mentors students, and teaches courses in immunology. She has expertise in molecular immunology, nanoparticle preparation, cell culture techniques, and has contributed to numerous research projects aimed at combating infectious diseases.
๐ฌ Research Interests:
Her research interests span molecular immunology and immunotherapy, focusing on vaccine development against leishmaniasis. Dr. Katebi is particularly interested in nanoparticle-based delivery systems, TLR agonists, and the immunomodulatory effects of extracellular vesicles derived from parasites.
๐ Awards:
Asal Katebi has received recognition for her contributions to immunological research, including awards for her presentations at international congresses. Notably, she was honored for her work on the SLA-R848-Pam3CSK4 combination as a therapeutic vaccine for cutaneous leishmaniasis.
๐ Publications:
Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection – Molecular Immunology, 2015
Leishmania tarentolae secreting PpSP15 and CpG motifs protects against Leishmania major infection – European Journal of Immunology, 2019
Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected macrophages – Biomedicine & Pharmacotherapy, 2021